For example, Sirukumab, the most advanced anti-IL-6 ligand monoclonal antibody, completed phase III trials but was rejected for approval for the treatment of active RA by the US FDA in August 2017 due to safety concerns. Here, IL6 is linked to rheumatoid arthritis.